Product Name:
ATM
Product Number:
ab-nk230
Target Full Name: Ataxia telangiectasia mutated protein-serine kinase
Target Alias: A-T, mutated; ATA; Ataxia telangiectasia mutated; Ataxia telangiectasia mutated homolog; ATC; ATD; ATDC; Kinase ATM; TEL1; TELO1; telomere maintenance 1; MGC74674; DKFZp781A0353; MGC74674; ENSG00000149311; Telomere maintenance 1
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK230
Antibody Target Type: Pan-specific
Protein UniProt: Q13315
Protein SigNET: Q13315
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human ATM sequence peptide Cat. No.: PE-01ARG99
Antibody Immunogen Sequence: CGKERRQLVKGRDDLR
Antibody Immunogen Description: Corresponds to amino acid residues G2719 to R2733
Production Method: Corresponds to amino acid residues G2719 to R2733
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human; Mouse; Rat
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 320-350 kDa.
Related Product 1: ATM blocking peptide
Related Product 2: ATM-1 pan-specific antibody (Cat. No.: AB-NK230-2)
Related Product 3: ATM-2 pan-specific antibody (Cat. No.: AB-NK230-1)
Related Product 4: ATM-3 pan-specific antibody (Cat. No.: AB-NK230-3)
Related Product 5: ATM-pS1981 phosphosite-specific antibody (Cat. No.: AB-PK526)
Related Product 6: ATM-pY2969 phosphosite-specific antibody (Cat. No.: AB-PK527)
Scientific Background: ATM is a protein-serine/threonine kinase of the Atypical group and PIKK family. Phosphorylation at S1981 increases phosphotransferase activity and induces interaction with ATM, NBS1 and p53. It acts as a DNA damage sensor and appears to be a tumour suppressor protein (TSP). Cancer-related mutations in human tumours point to a loss of function of the protein kinase. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. It regulates cell cycle progression checkpoints and induces DNA repair. It activates checkpoint signalling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA). It recognizes the substrate consensus sequence [S/T]-Q in many substrates. It phosphorylates and activates p53, while also inactivating the p53-inhibitor: MDM2. It phosphorylates S139 of the histone variant H2AX/H2AFX at double strand breaks (DSBs), which regulates the DNA damage response mechanism.. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, ATM acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, and prevents accessibility to the RAG complex and recombination of the second allele. It binds DNA ends, and it is part of the BRCA1- associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association appears to be a dynamic process changing throughout the cell cycle and within subnuclear domains. DNA damage promotes association with RAD17. It also phosphorylates p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9 and DCLRE1C. It is involved in the activation of ABL1 and JNK. It may function in vesicle and/or protein transport, replication-dependent histone mRNA degradation as well as have roles in T-cell development, gonad and neurological function.